Clinical Trial Update: Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity [Phase 3]

View source ↗

Summary

Phase 3 trial of setmelanotide (MC4R agonist) in Bardet-Biedl and Alström syndromes with obesity has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alström Syndrome
• Bardet-biedl Syndrome

Drugs mentioned

• Setmelanotide (setmelanotide)

Snippet

Sponsor: Rhythm Pharmaceuticals, Inc. | Conditions: Bardet Biedl Syndrome (BBS), Alström Syndrome (AS) | Phase 3 | Status: COMPLETED | Results posted: 2023-12-01